SCHEMBL1032275

SCHEMBL1032275

CNC(=O)Cc1ccccn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
POLB P06746 1/20 0.53
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
RAB9A P51151 2/20 0.50
LMNA P02545 2/20 0.50
GLS O94925 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
HRH3 Q9Y5N1 1/20 0.50
NPC1 O15118 1/20 0.50
ALDH1A1 P00352 2/20 0.49
ALOX15 P16050 2/20 0.49
TAAR1 Q96RJ0 1/20 0.49
SIGMAR1 Q99720 1/20 0.48
CYP1A2 P05177 1/20 0.47
TSHR P16473 1/20 0.47
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6796071 0.83 PDE5A (0.55) SMN1; SMN2POLBCA1CA2CA5A
SCHEMBL5032696 0.82 POLB (0.58) SMN1; SMN2POLBCA1CA2CA5A
SCHEMBL12851363 0.82 HRH3 (0.56) SMN1; SMN2LMNATDP1HRH3ALDH1A1
Dimethylamine SCHEMBL3686151 0.81 SMN1; SMN2 (0.53) SMN1; SMN2POLBRAB9ALMNATDP1
SCHEMBL29672808 0.81 CA1 (0.56) SMN1; SMN2POLBCA1CA2CA5A
SCHEMBL24015947 0.81 SMN1; SMN2 (0.53) SMN1; SMN2POLBCA1CA2CA5A
SCHEMBL966286 0.81 CA1 (0.56) SMN1; SMN2POLBCA1CA2CA5A
SCHEMBL22338187 0.81 POLB (0.50) SMN1; SMN2POLBCA1CA2CA5A
SCHEMBL12880515 0.81 L3MBTL1 (0.54) SMN1; SMN2POLBCA1CA2CA5A
SCHEMBL15433153 0.80 POLB (0.52) SMN1; SMN2POLBLMNAGLSTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 EP claimed
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 US claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 US claimed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 EP claimed
EP-1506196-B1 PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2012-01-18 EP claimed
WO-2011025541-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 WO claimed
EP-2035375-B1 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-01-19 EP claimed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP claimed
EP-1347974-B1 AMINOTRIAZOLOPYRIDIINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2004-11-03 EP claimed
CN-119923247-A Compositions with improved SPF and UVA photoprotection 西姆莱斯股份公司 2025-05-02 CN disclosed
CN-119604267-A Compositions with improved SPF and UVA photoprotection 西姆莱斯股份公司 2025-03-11 CN disclosed
US-11771695-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 US disclosed
WO-2005058874-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 WO disclosed
US-20050038010-A1 Substituted heterocyclic compounds and methods of use AMGEN, INC. 2005-02-17 US disclosed
EP-1506186-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2005-02-16 EP disclosed
WO-2003099808-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2003-12-04 WO disclosed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885POLB 2796/4885CA1 1259/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885POLB 2796/4885CA1 1259/4885
US-20050038010-A1 Substituted heterocyclic compounds and methods of use MYLK2, MYLK, MCL1 SMN1; SMN2 7/4885POLB 2945/4885CA1 738/4885
US-11771695-B2 Cannabinoid receptor modulators CNR2, CNR1, OPRL1 SMN1; SMN2 2187/4885POLB 4384/4885CA1 2434/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885POLB 2796/4885CA1 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.